November 7, 2026
Every successful investor knows a painful truth: knowing when to sell is often more critical than knowing what to buy.
While financial media overwhelmingly focuses on buying opportunities, our research consistently identifies companies facing significant headwinds that merit serious consideration for selling. These aren’t just stocks underperforming the market; they’re businesses confronting structural challenges, deteriorating fundamentals, or carrying valuations disconnected from financial reality.
What you won’t find here: reactionary calls based on short-term price movements or headline volatility. Each company on this list has been thoroughly analyzed across multiple metrics that historically precede substantial declines.
Smart investors understand that portfolio management requires both addition and subtraction. Sometimes the best investment decision is to redeploy capital away from troubling positions before problems fully materialize in the share price.
This week’s watchlist highlights stocks showing critical weaknesses that demand immediate attention:
Marvell Technology (MRVL)
Marvell is caught between two pressures at once: a policy shift that threatens its end market, and a large acquisition that could dilute shareholders for years. Shares fell roughly 13% on Thursday, November 5, as investors sold chip and AI infrastructure stocks after the midterm results. The sell-off was broad, with the S&P 500 down about 4% and the Nasdaq Composite down about 5% at the time of the report. Marvell’s networking chips move data inside AI data centers, which puts the company directly in the path of the new governors in Texas, Ohio and Georgia, all major data center states, who have promised construction moratoriums.
The Lumentum deal makes the picture harder. On Monday, Marvell agreed to buy AI photonics maker Lumentum in an all-stock transaction valued at $115 billion. That structure is a double-edged sword. Issuing that much stock would significantly dilute existing shareholders, and because the price of the shares being offered falls as Marvell’s stock falls, a further slide raises the risk that the deal is renegotiated on less favorable terms for Marvell holders or collapses altogether. Neither outcome is good for shareholders who are already holding a stock under pressure.
At around $141 per share, Marvell carries a market capitalization of about $124 billion and trades in a 52-week range of $70.69 to $329.88. The stock has more than doubled over the past year in many stretches, so the drop reflects how much optimism was built into the price. A gross margin of 51.42% reflects a strong business, but that business is tied to AI data center spending that now faces regulatory and financing uncertainty. For semiconductor investors, Marvell is a company where the policy backdrop and a dilutive deal can compound each other, and the stock offers little reason to wait for clarity.
Northrop Grumman (NOC)
Northrop Grumman fell 3.7% on Wednesday without any company-specific news, and the reason is the election. Democrats now control both chambers of Congress, and the $1.5 trillion defense budget that the administration proposed for fiscal 2027 looks increasingly out of reach. Even before the vote, the Pentagon was reportedly preparing to cut its request to about $1.1 trillion. A Congress that is hostile to the Iran war and controls the power of the purse is unlikely to approve even that level in full. No analysts have downgraded the stock yet, but the funding outlook is a clear reason for investors to reassess.
The valuation makes it harder to hold through that reassessment. Northrop trades at about 18 times earnings, which looks reasonable on the surface. But the stock sits at 1.8 times sales, a historically high level for the defense sector, and free cash flow covers less than $0.63 for every $1 of reported earnings. That gap suggests the reported profit is not converting into cash at the rate the multiple assumes. A company priced for steady defense spending growth has less margin for error if that spending stalls.
At around $525 per share, Northrop has a market capitalization of about $75 billion and trades within a 52-week range of $470.06 to $774.00. The 1.82% dividend yield offers some support, but the stock is already well off its highs, and the business is facing a funding environment that has shifted against it. For defense investors, the risk is not an earnings collapse but a multiple built on assumptions about government spending that have just become less certain.
Thomson Reuters (TRI)
Thomson Reuters delivered growth and still disappointed, and the shares fell about 5% on Tuesday. Revenue rose 10% to $1.83 billion, and adjusted net income grew at a similar pace to $350 million, or $0.81 per share. But analysts had expected nearly $1.91 billion in revenue and $0.89 per share, so the company missed on both lines. The growth came from its “big three” segments, legal professionals, corporates, and tax, audit and accounting clients, which together made up 88% of third-quarter revenue and grew 10% year over year.
The company also raised its 2026 revenue growth forecast to 9.5% from 8%, though that revision partly reflects the sale of its global print business on October 1. The guidance change matters less than the fact that the stock was priced for a much stronger beat. Thomson Reuters trades at a price-to-earnings-to-growth ratio of about 4.7, where a reading near 1 is generally considered fairly valued. Investors were clearly expecting a convincing double beat, and a modest miss exposed how much of the premium depends on sustained execution.
At around $113 per share, Thomson Reuters has a market capitalization of about $49 billion and is down about 9% year to date. The 2.27% dividend yield and 26.21% gross margin are solid, but the stock’s 52-week range of $76.28 to $142.07 shows how far expectations have swung. For investors, Thomson Reuters is a well-run business that is still expensive for the growth it delivers, and the valuation leaves little room for another disappointment.
